346 related articles for article (PubMed ID: 36040480)
1. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
Saugues S; Lambert C; Daguenet E; Ansah HJ; Turhan A; Huguet F; Guerci-Bresler A; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
Ann Hematol; 2022 Oct; 101(10):2241-2255. PubMed ID: 36040480
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
3. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
4. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
5. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Rea D; Nicolini FE; Tulliez M; Guilhot F; Guilhot J; Guerci-Bresler A; Gardembas M; Coiteux V; Guillerm G; Legros L; Etienne G; Pignon JM; Villemagne B; Escoffre-Barbe M; Ianotto JC; Charbonnier A; Johnson-Ansah H; Noel MP; Rousselot P; Mahon FX;
Blood; 2017 Feb; 129(7):846-854. PubMed ID: 27932374
[TBL] [Abstract][Full Text] [Related]
7. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
Wang R; Cong Y; Li C; Zhang C; Lin H
Medicine (Baltimore); 2019 Apr; 98(15):e15222. PubMed ID: 30985724
[TBL] [Abstract][Full Text] [Related]
9. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX
Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142
[TBL] [Abstract][Full Text] [Related]
12. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
[TBL] [Abstract][Full Text] [Related]
13. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
Yoshida C; Yamaguchi H; Doki N; Murai K; Iino M; Hatta Y; Onizuka M; Yokose N; Fujimaki K; Hagihara M; Oshikawa G; Murayama K; Kumagai T; Kimura S; Najima Y; Iriyama N; Tsutsumi I; Oba K; Kojima H; Sakamaki H; Inokuchi K;
Int J Hematol; 2023 May; 117(5):694-705. PubMed ID: 36739328
[TBL] [Abstract][Full Text] [Related]
14. Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Ferreira APS; Seguro FS; Abdo ARN; Santos FM; Maciel FVR; Nardinelli L; Giorgi RR; Ruiz ARL; Ferreira MPS; Rego EM; Rocha V; Bendit I
Ann Hematol; 2023 Jul; 102(7):1761-1771. PubMed ID: 37052662
[TBL] [Abstract][Full Text] [Related]
15. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Milojkovic D; Apperley JF; Gerrard G; Ibrahim AR; Szydlo R; Bua M; Reid A; Rezvani K; Foroni L; Goldman J; Marin D
Blood; 2012 Feb; 119(8):1838-43. PubMed ID: 22174159
[TBL] [Abstract][Full Text] [Related]
16. [Effect of stopping tyrosine kinase inhibitors during pregnancy on disease status and reproductive outcomes among patients with chronic myeloid leukemia].
Zhao HF; Zhang Y; Li Z; Zhou J; Zu YL; Yu FK; Gui RR; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):540-545. PubMed ID: 30122011
[No Abstract] [Full Text] [Related]
17. Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Etienne G; Faberes C; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Fort MP; Bijou F; Turcq B; Robbesyn F; Durrieu F; Versmée L; Madene S; Moldovan M; Katsahian S; Charles-Nelson A; Lascaux A; Mahon FX; Dulucq S
Cancer Med; 2021 Jun; 10(11):3635-3645. PubMed ID: 33988316
[TBL] [Abstract][Full Text] [Related]
18. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
Cortes J; Rea D; Lipton JH
Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563
[TBL] [Abstract][Full Text] [Related]
19. A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia.
Cantoni N; Sommavilla R; Seitz P; Kulenkampff E; Kahn S; Lambert JF; Schmidt A; Zenhaeusern R; Balabanov S
BMC Cancer; 2022 Nov; 22(1):1192. PubMed ID: 36402993
[TBL] [Abstract][Full Text] [Related]
20. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Perusini MA; Novitzky-Basso I; Atenafu EG; Forrest D; Bence-Bruckler I; Savoie L; Keating MM; Busque L; Delage R; Xenocostas A; Liew E; Laneuville P; Paulson K; Stockley T; Lipton JH; Leber B; Kim DDH
Br J Haematol; 2023 Dec; 203(5):781-791. PubMed ID: 37697469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
